Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy

References

• YoussefKKVan KeymeulenALapougeGIdentification of the cell lineage at the origin of basal cell carcinomaNat Cell Biol201012329930520154679
   PubMed Web of Science ®Google Scholar
• WangGYWangJManciantiMLEpsteinEHJrBasal cell carcinomas arise from hair follicle stem cells in Ptch1(+/–) miceCancer Cell201119111412421215705
   PubMed Web of Science ®Google Scholar
• MarzukaAGBookSEBasal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and managementYale J Biol Med201588216717926029015
   PubMedGoogle Scholar
• GallagherRPHillGBBajdikCDSunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinomaArch Dermatol199513121571637857111
   PubMedGoogle Scholar
• MarcilISternRSRisk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysisArch Dermatol2000136121524153011115165
   PubMedGoogle Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer, Version 1.2015NCCN Available from: https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/nmsc.pdfAccessed January 26, 2016
   Google Scholar
• Von HoffDDLoRussoPMRudinCMInhibition of the hedgehog pathway in advanced basal-cell carcinomaN Engl J Med2009361121164117219726763
   PubMed Web of Science ®Google Scholar
• LoRussoPMRudinCMReddyJCPhase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumorsClin Cancer Res20111782502251121300762
   PubMed Web of Science ®Google Scholar
• LoRussoPMJimenoADyGPharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumorsClin Cancer Res201117175774578221753154
   PubMed Web of Science ®Google Scholar
• SekulicAMigdenMROroAEEfficacy and safety of vismodegib in advanced basal-cell carcinomaN Engl J Med2012366232171217922670903
   PubMed Web of Science ®Google Scholar
• SekulicAMigdenMRLewisKPivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCCJ Am Acad Dermatol201572610211026.e825981002
   PubMed Web of Science ®Google Scholar
• SekulicAMigdenMRBasset-SeguinNLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (aBCC): 18-month update of the pivotal ERIVANCE BCC studyJ Clin Oncol201331Suppl abstr 9037
   Google Scholar
• SekulicAMigdenMROroALong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC studyPoster presented at: 22nd EADV CongressOctober 2–6, 2013Istanbul, Turkey
   Google Scholar
• SekulicAMigdenMRBasset-SeguinNLong-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC studyJ Clin Oncol2014325s Suppl; abstr 9013
   Web of Science ®Google Scholar
• ChangALSolomonJAHainsworthJDExpanded access study of patients with advanced basal cell carcinoma treated with the hedgehog pathway inhibitor, vismodegibJ Am Acad Dermatol2014701606924189279
   PubMed Web of Science ®Google Scholar
• ChangALArronSTMigdenMRSafety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trialsOrphanet J Rare Dis201611112027581207
   PubMed Web of Science ®Google Scholar
• ChangALLewisKDArronSTSafety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinomaOncotarget2016746761187612427764798
   PubMedGoogle Scholar
• Basset-SeguinNHauschildAGrobJJVismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialLancet Oncol201516672973625981813
   PubMed Web of Science ®Google Scholar
• TangJYMackay-WigganJMAszterbaumMInhibiting the hedgehog pathway in patients with the basal-cell nevus syndromeN Engl J Med2012366232180218822670904
   PubMed Web of Science ®Google Scholar
• TangJYAllyMSChananaAMInhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trialLancet Oncol201617121720173127838224
   PubMed Web of Science ®Google Scholar
• SofenHGrossKGGoldbergLHA phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinomaJ Am Acad Dermatol20157319910525913533
   PubMed Web of Science ®Google Scholar
• ViscusiKSHankeCWVismodegib for locally advanced basal cell carcinoma: descriptive analysis of a case series and comparison to the literatureJ Drugs Dermatol201514995696226355613
   PubMed Web of Science ®Google Scholar
• AllyMSAasiS1WysongAAn investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinomaJ Am Acad Dermatol201471590491124929884
   PubMed Web of Science ®Google Scholar
• KwonGPAllyMSBailey-HealyIUpdate to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC)J Am Acad Dermatol201675121321527317518
   PubMed Web of Science ®Google Scholar
• OzgurOKYinVChouEHedgehog pathway inhibition for locally advanced periocular basal cell carcinoma and basal cell nevus syndromeAm J Ophthalmol2015160222022725935097
   PubMed Web of Science ®Google Scholar
• GillHSMoscatoEEChangALSoonSSilkissRZVismodegib for periocular and orbital basal cell carcinomaJAMA Ophthalmol2013131121591159424136169
   PubMed Web of Science ®Google Scholar
• AlarconIPasqualiPMalvehyJPuigSTumor regrowth and development of keratinocytic neoplasms in patients under smoothened inhibition: in vivo assessment with reflectance confocal microscopySkin Res Technol Epub20161027
   Web of Science ®Google Scholar
• MohanSVChangJLiSHenryASWoodDJChangALIncreased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinomaJAMA Dermatol2016152552753226914338
   PubMed Web of Science ®Google Scholar
• GjersvikPStudy on the risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma: not a case–control studyJAMA Dermatol2016152101172
   Web of Science ®Google Scholar
• PuigSSampognaFTejera-VaquerizoAStudy on the risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma: not a case–control studyJAMA Dermatol20161521011721173
   Web of Science ®Google Scholar
• LacoutureMEDrénoBAsciertoPACharacterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinomaOncologist201621101218122927511905
   PubMed Web of Science ®Google Scholar
• DrenoBKunstfeldRHauschildATwo intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trialLancet Oncol201718340441228188086
   PubMed Web of Science ®Google Scholar